New hope for lymphoma patients Who've run out of options
NCT ID NCT05464329
Summary
This early-stage study is testing whether adding a new immunotherapy drug called mosunetuzumab to standard chemotherapy is safe and effective for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The trial will enroll 24 participants to see if this combination can help control the cancer better than current approaches. Researchers will closely monitor side effects and how well the cancer responds to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.